Key result
ZEB1-AS1 knockdown reduces isoproterenol-induced hypertrophy in AC16 cells via the miR-186-5p/HDAC2 axis.
Why the study?
The role of the long noncoding RNA ZEB1-AS1 in cardiac hypertrophy remains unclear.
Does knockdown of ZEB1-AS1 reduce hypertrophic responses in isoproterenol-stimulated AC16 cells?
Does knockdown of ZEB1-AS1 reduce hypertrophic responses in isoproterenol-stimulated AC16 cells?
The ZEB1-AS1/miR-186-5p/HDAC2 axis contributes to cardiac hypertrophy, suggesting ZEB1-AS1 as a potential therapeutic target for clinical intervention.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ZEB1-AS1 inhibition in hypertrophy models; leaves open clinical translation from cell data.
BACKGROUND: The role of the long noncoding RNA ZEB1-AS1 in cardiac hypertrophy (CH) remains unclear. OBJECTIVES: To investigate the function of ZEB1-AS1 in the development and progression of CH as well as elucidate its underlying molecular mechanism. METHODS: RNA expression levels were quantified by quantitative real-time PCR. Surface area of AC16 cells was assessed by immunofluorescence staining. Protein expression was evaluated by Western blotting. Interactions among RNAs were examined using luciferase reporter assays and RNA immunoprecipitation. Statistical significance was set at p < 0.05. RESULTS: The expression of ZEB1-AS1 was upregulated in myocardial tissues and in isoproterenol (ISO)-stimulated AC16 cells. The knockdown of ZEB1-AS1 mitigated ISO-induced hypertrophic responses. Mechanistically, ZEB1-AS1 modulated histone deacetylase 2 (HDAC2) expression by acting as a molecular sponge for miR-186-5p. Consistently, the knockdown of ZEB1-AS1 reduced HDAC2 and decreased the expression of hypertrophic markers, including B-type natriuretic peptide, atrial natriuretic peptide, and β-myosin heavy chain, thereby restraining the progression of CH. CONCLUSIONS: ZEB1-AS1 is upregulated in myocardial tissues and ISO-stimulated AC16 cells. Our findings indicate the ZEB1-AS1/miR-186-5p/HDAC2 axis contributes to CH, providing a mechanistic basis and potential therapeutic target for clinical intervention.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2025) studied Cardiac hypertrophy. Knockdown of ZEB1-AS1 was evaluated on Hypertrophic responses and expression of hypertrophic markers. Knockdown of ZEB1-AS1 mitigated isoproterenol-induced hypertrophic responses and reduced HDAC2 and hypertrophic markers in AC16 cells via the miR-186-5p/HDAC2 axis.
Synapse has enriched 10 related papers. Consider them for comparative context: